

A single dose two-phase crossover study to assess the tolerability and pharmacokinetic parameters of a fixed dose formulation of artesunate-mefloquine and standard dose artesunate and mefloquine as loose tablets in healthy normal volunteers (Thailand)

Submission date 12/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 01/02/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 28/03/2017	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr W Taylor

Contact details
20, Avenue Appia
Geneva-27
Switzerland
CH 1211
-
taylorw@who.int

Additional identifiers

Protocol serial number
RPC117

Study information

Scientific Title

A single dose two-phase crossover study to assess the tolerability and pharmacokinetic parameters of a fixed dose formulation of artesunate-mefloquine and standard dose artesunate and mefloquine as loose tablets in healthy normal volunteers (Thailand)

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Received from the local medical ethics committee on 27/05/2005

Study design

Single dose two-phase crossover study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Pharmacokinetics of drug

Interventions

Two tablets of fixed dose artesunate and mefloquine, given once: total dose = AS 200mg, MQ 400 mg.

Loose tablets - 200 mg of artesunate (4 tablets) and 500 mg of mefloquine (2 tablets).

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Artesunate, mefloquine

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

25/02/2006

Eligibility

Key inclusion criteria

1. Age 18 to 50 years
2. Written consent given after reading the volunteer information leaflet. Participation must be voluntary and volunteers will be fully informed of possible side effects. They will be informed that they are free to withdraw at any time
3. No significant abnormal findings on history or examination, particularly no prior liver disease, cardiovascular disease (including arrhythmias), peripheral neuropathy, convulsions, and psychiatric disease
4. No clinically significant abnormalities on:
 - 4.1. Haematology:
 - 4.1.1. Haemoglobin: male 13.6 - 17.5 g/dl, female 12 - 15.5 g/dl
 - 4.1.2. Total white cell count: $4 - 10 \times 10^3/\text{ul}$
 - 4.1.3. Platelet counts: $150 - 450 \times 10^3/\text{ul}$
 - 4.2. Liver:
 - 4.2.1. Total bilirubin less than 1.2 mg/dl
 - 4.2.2. Serum Glutamic Oxaloacetic Transaminase (SGOT) less than or equal to 35 IU/l
 - 4.2.3. Serum Glutamic Pyruvic Transaminase (SGPT) less than or equal to 35 IU/l
 - 4.3. Renal function:
 - 4.3.1. Creatinine 50 - 100 $\mu\text{mol/l}$
 - 4.3.2. Blood urea nitrogen 8 - 20 mg/dl
5. Negative pregnancy test (women) using the urine beta Human Chorionic Gonadotropin (βHCG)
6. Normal electrocardiogram (physicians reading: running at 50 mm/sec)
7. No history of antimalarial ingestion (chloroquine, amodiaquine, quinine, halofantrine, pyrimethamine-sulfadoxine) in the preceding two months, and for mefloquine, preceding three months
8. No other drugs or medications, including over-the counter preparations, ingested in the preceding week
9. Adequate venous access
10. Not participating in another clinical trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Refusal of consent
2. Clinically significant physical signs detected by the examining physician
3. Abnormal electrocardiogram detected by the examining physician
4. Presence of hepatic, renal and gastrointestinal disorders
5. Smokers (greater than 10 cigarettes/day), abuse of alcohol or recreational drugs
6. Presence of malaria parasites on a thick smear
7. Subjects having been in a malarial area in the preceding eight weeks
8. Subjects having ingested drugs in the preceding week
9. Presence of acute or chronic infections
10. Allergy to study drugs

Date of first enrolment

25/02/2005

Date of final enrolment

25/02/2006

Locations

Countries of recruitment

Switzerland

Thailand

Study participating centre

20, Avenue Appia

Geneva-27

Switzerland

CH 1211

Sponsor information

Organisation

Drugs for Neglected Diseases initiative (DNDi) (Switzerland)

ROR

<https://ror.org/022mz6y25>

Funder(s)

Funder type

Research organisation

Funder Name

Drugs for Neglected Diseases initiative (DNDi) (Switzerland)

Funder Name

Confirming the International Role of Community Research for Development - Developing Countries (INCO-DEV)

Funder Name

European Commission (ref: ICA4-2001-10193)

Alternative Name(s)

European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location**Funder Name**

United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP) /World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary****Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/06/2010		Yes	No